NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Related Questions
How will the lawsuit investigation by Pomerantz LLP affect Dyne Therapeutics' short‑term stock volatility and liquidity?
What potential financial exposure or settlement costs could arise from the claims, and how might that impact Dyne's earnings guidance?
Are there any precedents or similar investor‑class actions in the biotech sector that could inform the likely outcome and market reaction?